Journal issues > Issue 2, March 2024 > Radiotherapy as bridging strategy in large B-cell lymphoma patients selected for CAR T-cell therapy

Radiotherapy as bridging strategy in large B-cell lymphoma patients selected for CAR T-cell therapy

By: A.G.H. Niezink MD, R.W.M. van der Maazen MD, PhD, B.D.P. Ta MSc, H. Vos-Westerman MD, C.P.M. Janus MD, L.A. Daniels MD, PhD

SUMMARY

Chimeric antigen receptor T-cell (CAR T-cell) therapy is available in the Netherlands as a third-line treatment option in patients with large B-cell lymphoma. Bridging is often required during the waiting period between leukapheresis and CAR T-cell infusion. Radiotherapy is an increasingly applied bridging strategy, which is well tolerated by patients and also safe and effective. The most commonly used radiation schedule is 20 Gy in five fractions. In addition to bridging, radiotherapy can also be used as consolidation or salvage treatment after CAR T-cell therapy. Involving a radiation oncologist in a timely manner for patients who are going to be treated with CAR T-cell therapy is of benefit.

(BELG J HEMATOL 2024;15(2):37–42)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top